Sinopharm International is a wholly-owned subsidiary of Sinopharm, which dedicates to be a technology-driven global enterprise that is leading domestically while influential internationally and constantly meet people's needs for a healthy and better life. With a registered capital of 5 billion yuan, Sinopharm International covers international operations, nutrition and health, tax-free business and health care. In 2021, the sales revenue of Sinopahrm International reached RMB 59.2 billion, with an excellent import and export volume of USD 7.6 billion.

As the strategic international business platform in the field of pharmaceuticals and health for Sinopharm, Sinopharm International has actively participated in the global mainstream pharmaceutical market, with overseas networks covering 5 continents and international business throughout the world. Sinopharm International builds close cooperative relationships with more than 100 world-renowned suppliers of medicine, medical devices and health products, dealing with over 195 countries, regions and international organizations.

The Nutrition and Health business serves‘Healthy China’strategy, based on the advantages of international trade, fully integrates Sinopharm's business advantages in the whole life cycle, full service, whole industry chain, and whole ecosystem in the field of medicine, medical treatment and health. With its self-owned brands, distribution brands, and exclusive agent brands from Japan, South Korea, Europe, and the US, a total of more than 200 well-known health brands, more than 1000 SKU, is committed to make China Sinopharm Healthcare Industry Company, a subsidiary of Sinopharm International, become the modern life and health flagship enterprise of trade, industry and technology integration.

Focusing on the international pharmaceutical and health sectors, Sinopharm International has actively strategized to invest in strategic emerging industries and future health-related sectors, as well as to foster the development of new quality productive forces, which has led to the establishment of Sinopharm Seragon, a joint venture at the forefront of global aging intervention technologies, Sinopharm-Microcyto, a joint venture specializing in cutting-edge biomanufacturing of allulose(psicose), and Sinopharm-Elekta(Beijing) Medical Technology CO., LTD., the first state-owned international medical equipment joint venture in radiotherapy. Sinopharm International has established and co-built four biosynthesis and pilot-scale testing laboratories. In 2023, Sinopharm International has been granted five new national patents with a steady enhancement in independent pharmaceutical technology research and development.

Sinopharm China National Service Cooperation (“Sinopharm CNSC”) was the first national duty-free company approved by the State Council in China, whose duty-free business could be dated back to 1980. Leveraging the advantages of international trade, it initiates an all-rounded business model, covering downtown, border, airport, port, offshore, overseas and online, and strives to create a duty-free business of the nation, of national, Sinopharm, and internationalization. It owns more than 30 duty-free stores and branches worldwide, providing a global shopping experience to Chinese citizens without going abroad.

To implement the national strategy of actively responding to population ageing and taking advantage of medical resources, by incorporating the philosophies of "positive ageing" and "healthy ageing" into the entire process of developing integrated medical and aging care services, Sinopharm International is exploring the establishment of a diverse operational system. This system aims to blend medical care, health care, and cultural care, creating an inclusive and high-quality cluster that offers integrated services covering combined medical and ageing care, rehabilitation and ageing, migratory retirement, nursing facilities, traditional Chinese medicine therapy, palliative care, senior education, and international retirement solutions and so on. Now, 54 health care bases of Sinopharm International are located in 33 cities of 20 provinces in China.

Since the outbreak of the COVID-19 pandemic, in accordance with the important instructions and directives of General Secretary Xi Jinping and the decisions and deployments of the CPC Central Committee and the State Council, Sinopharm International has diligently fulfilled its role as the national team, main force, and pillar of central enterprises in the fight against the pandemic. Following the requirements of the State-owned Assets Supervision and Administration Commission of the State Council and Sinopharm Group, Sinopharm International has undertaken the critical task of providing foreign aid and exporting anti-pandemic supplies. Sinopharm International has shipped over 4 billion pieces of medical protective equipment to 173 countries and regions, and exported and donated Sinopharm COVID-19 vaccines to 120 countries, regions, and international organizations, covering populations in 196 countries. Sinopharm International has been recognized with the honor of being named a National Advanced Collective in the Fight Against COVID-19.